ENDRA Life Sciences Inc. reported a net loss of $7.03 million for the fiscal year ending December 31, 2025, a decrease from the $11.51 million loss recorded in the previous year. The company's total revenue remains at zero, as it has not yet commercialized its TAEUS technology platform, which is designed for non-invasive liver fat measurement. Research and development expenses decreased by 42% to $1.85 million, reflecting a strategic shift towards cost reduction and prioritization of product development over clinical activities. General and administrative expenses also saw a significant reduction, dropping 47% to $3.72 million, primarily due to a non-cash inventory reserve recorded in 2024.
In terms of operational changes, ENDRA has implemented a series of cost-cutting measures, including a reduction in workforce, to extend its financial runway and focus on product improvements and regulatory strategies. As of December 31, 2025, the company had a cash balance of $762,365 and an accumulated deficit of $110.47 million. The company is actively exploring strategic alternatives, including potential mergers or collaborations, to maximize shareholder value. However, it faces significant challenges in securing additional financing to support ongoing operations and product development.
ENDRA's digital asset treasury strategy, initiated in 2025, involves holding cryptocurrencies as part of its capital management efforts. As of the end of 2025, the company held approximately $2.01 million in digital assets, primarily HYPE tokens, which are subject to market volatility. The company reported a loss of $995,161 related to changes in the fair value of these digital assets during the year. The management's outlook remains cautious, emphasizing the need for additional capital to fund operations and the potential for further strategic evaluations.
The company has reduced its employee count from 11 to 4 as part of its restructuring efforts, and it continues to assess the market for its TAEUS technology, which targets the growing need for effective liver fat diagnostics amid rising metabolic disease rates. ENDRA's future plans include pursuing regulatory approvals for its TAEUS applications in the U.S. and Europe, with the aim of establishing a subscription-based revenue model. However, the timeline for these developments may be impacted by the ongoing need for additional funding and the completion of necessary clinical trials.
About ENDRA Life Sciences Inc.
ENDRA Life Sciences develops advanced ultrasound-based platforms, primarily TAEUS, for non-invasive detection and monitoring of liver fat and metabolic diseases. Its core focus is on creating scalable, cost-effective diagnostic tools leveraging thermoacoustic technology, AI integration, and existing ultrasound systems. Serving pharmaceutical, clinical, and medical markets globally, the company aims to improve early diagnosis, disease management, and therapeutic monitoring for conditions like fatty liver disease and obesity.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.